<DOC>
	<DOCNO>NCT00006476</DOCNO>
	<brief_summary>RATIONALE : Suramin may stop growth bladder cancer stop blood flow tumor . PURPOSE : Phase I trial study effectiveness suramin treat patient recurrent bladder cancer .</brief_summary>
	<brief_title>Suramin Treating Patients With Recurrent Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) suramin patient recurrent superficial bladder cancer . - Confirm significant systemic absorption drug administer intravesically patient . OUTLINE : This dose escalation study . At approximately 14-18 day surgical resection bladder tumor ( ) , patient receive intravesicular suramin via urethral catheter installation bladder 2 hour weekly 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos suramin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient develop dose-limiting toxicity . Patients follow 2-4 week . PROJECTED ACCRUAL : A total 12-15 patient accrue study 1 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Suramin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent superficial bladder cancer Intermediate prognosis define follow : Recurrent , multiple Ta , T1 carcinoma Multiple ( 17 ) tumor Tumors resect previously must histological grade G1 G2 OR Previously treat superficial bladder cancer require followup cystoscopy Recurrent disease diagnose surgery No tumor invasion muscle carcinoma situ PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Platelet count least 150,000/mm3 Hepatic : No clinically significant hepatic disease Renal : Creatinine clearance great 60 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study No history adrenal insufficiency No malignancy within past 5 year except adequately treat conebiopsied carcinoma situ cervix nonmelanoma skin cancer No history difficult catheterization No confusion disorientation No condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroid Radiotherapy : No prior radiotherapy bladder No concurrent radiotherapy Surgery : See Disease Characteristics At least 4 week since prior major thoracic abdominal surgery Other : Recovered prior therapy stable 4 week At least 6 week since prior intravesicular therapy No prior concurrent investigational drug No concurrent anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>stage 0 bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
</DOC>